Deal or Case news
26.02.2021
NautaDutilh assisted InflaRx N.V. with its underwritten public offering of ordinary shares and warrants with a gross proceeds for InflaRx of USD 75 million. The shares are being sold at a public offering price of USD 5.00 per share.

For each share purchased, an investor will also receive a warrant to purchase a common share at an exercise price of USD 5.80. The warrants are exercisable immediately and have a term of up to one year.

InflaRx is a Nasdaq listed clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx is a client of NautaDutilh since 2017. 

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.